Unrestricted Cash and Cash Equivalents: Over $270.4 million. Vertex Inc (NASDAQ:VERX) reported a strong start to 2025 with a 12.9% year-over-year increase in revenue, reaching $177.1 million.

Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Solar financing platform Metafin on Tuesday said it raised $10 million in a Series A funding round led by Vertex Ventures Southeast Asia and India. The round, a mix of equity and debt, also saw ...

Google updated the documentation for the Google-Extended user agent, which publishers can use to control whether Google Gemini and Vertex use their data for training purposes or for grounding AI ...

The scenarios can be repeated as often as it takes for good habit patterns to form. Vertex Solutions’ ITDs are utilized for the U.S. Air Force and Navy’s undergraduate pilot training ...

Google Cloud’s latest enhancements to Vertex AI and the Gemini model family offer businesses a comprehensive solution for building, deploying, and managing AI applications with unprecedented ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

U.S. pharma imports hit $200 billion in 2024, a 10% tariff could cost the sector $20 billion. Vertex and Alnylam are seen as most resilient to tariff, tax and Medicaid risks. Memorial Day Special ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...

With suzetrigine, developed by pharmaceutical company Vertex, they finally succeeded. The FDA’s approval is based on two phase 3 clinical trials conducted in patients after tummy tuck and bunion ...

Its manufacturer Vertex Pharmaceuticals said this enables it to provide effective relief for moderate to severe pain without "the addictive potential of opioids". The US has been grappling with a ...